The Proteins of Type IV Secretion System as Promising Candidates for Helicobacter Pylori Vaccine

Davood Esmaeili

Authors

Davood Esmaeili

Keywords:

Abstract

Helicobacter. pylori is a component of class 1 carcinogens and there is a close association between the incidence of gastric cancer and high prevalence of infection with this bacterium. The risk of gastric cancer associated with H. pylori infection in industrialized and developing countries is estimated to be 80% and 70% respectively. CagA is the important virulence factor in this bacterium and all of the strains involved in gastric cancer are CagA positive. This factor is secreted into host cells by type IV secretion system. CagA and type IV secretion system in H. pylori encoded by the cag pathogenicity islands (cag PAI) that encodes 30 proteins which are necessary for the pilus formation and function of type IV secretion system, so regarding to the role of this secretion system in secreting CagA and its function in pathogenesis and cancer development in humans and the role of different proteins of this secretion system such as canal and pilus formation and their necessity for function of these structures, it is possibly they are be appropriate candidates for design vaccine, because with inhibiting these proteins can stop canal and pilus formation and finally hinder CagA secretion into the host cells.

Downloads

How to Cite

The Proteins of Type IV Secretion System as Promising Candidates for Helicobacter Pylori Vaccine. (2015). Global Journal of Medical Research, 15(22), 39-42. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

Cai J-P, Cheng J-W, Ma X-Y, Li Y-Z, Li Y, Huang X (2012) Lack of association of conjunctival MALT lymphoma with Chlamydiae or Helicobacter pylori in a cohort of Chinese patients. (2), BR84.

Makola D, Peura DA, Crowe SE (2007) Helicobacter pylori infection and related gastrointestinal diseases Journal of clinical gastroenterology. 41(6), 548-558.

Moodley Y, Linz B, Bond RP, Nieuwoudt M, Soodyall H, Schlebusch CM (2012) Age of the association between Helicobacter pylori and man. 8(5), e1002693.

Pacifico L, Anania C, Osborn JF, Ferraro F, Chiesa C (2010) Consequences of Helicobacter pylori infection in children. 16(41), 5181.

T. Azuma, J. Konishi, Y. Tanaka, M. Hirai, S. Ito, T. Kato (1994) Contribution of HLA-DQA gene to host's response against Hellcobacter pylori The Lancet. 343(8896), 542-543.

Lam Wong BC-Y, Chen Wong WM, Feng Zheng TT (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial Jama. 291(2), 187. https://doi.org/10.1001/jama.291.2.187

D. Parkin, C. Muir, S. Whelan, Y. Gao, J. Ferlay, J. Powell (1992) Cancer incidence in five continents. Volume VI.

De A, Baldi A, Russo P, Todisco A, Altucci L, Giardullo N (2003) Coexpression of Helicobacter pylori's proteins CagA and HspB induces cell proliferation in AGS gastric epithelial cells, independently from the bacterial infection. 63(19), 6350-6.

J. Kusters (2001) Recent developments in Helicobacter pylori vaccination Scandinavian Journal of Gastroenterology. 36(234), 15-21. https://doi.org/10.1080/003655201753265406

Xavier Calvet, María‐josé Ramírez Lázaro, Philippe Lehours, Francis Mégraud (2013) Diagnosis and epidemiology of Helicobacter pylori infection Helicobacter. 18(s1), 5-11. https://doi.org/10.1111/hel.12071

Yaron Niv (2008) Niv Y. H pylori recurrence after successful eradication. 14(10), 1477. https://doi.org/10.3748/wjg.14.1477

Robinson K, Argent RH, Atherton JC (2007) The inflammatory and immune response to Helicobacter pylori infection Best Practice & Research Clinical Gastroenterology. 21(2), 237-259.

Taylor JM, Ziman ME, Huff JL, Moroski NM, Vajdy M, Solnick JV (2006) Helicobacter pylori lipopolysaccharide promotes a Th1 type immune response in immunized mice Vaccine. 24(23), 4987-4994.

Del G, Covacci A, Telford JL, Montecucco C, Rappuoli R (2001) The design of vaccines against Helicobacter pylori and their development Annual review of immunology. 19(1), 523-563.

Svennerholm Nyström J (2007) Oral immunization with HpaA affords therapeutic protective immunity against H pylori that is reflected by specific mucosal immune responses Vaccine. 25(14), 2591-2598.

Every AL, Stent A, Moloney MB, Ng GZ, Skene CD, Edwards SJ (2011) Evaluation of superoxide dismutase from Helicobacter pylori as a protective vaccine antigen Vaccine. 29(7), 1514-1518.

Hongying F, Xianbo W, Fang Y, Yang B, Beiguo L (2014) Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin hp0410 of Helicobacter pylori induces mucosal and systemic immune responses Clinical and Vaccine Immunology. 21(2), 126-132.

Stent A, Every AL, Ng GZ, Chionh YT, Ong LS, Edwards SJ (2012) Helicobacter pylori thiolperoxidase as a protective antigen in single-and multi-component vaccines Vaccine. 30(50), 7214-7220.

Zeng Lü L, Shen Wang P-l, Mei Xiang T-x (2011) Oral immunization with recombinant Mycobacterium smegmatis expressing the outer membrane protein 26-kilodalton antigen confers prophylactic protection against Helicobacter pylori infection Clinical and Vaccine Immunology. 18(11).

O'Riordan AA, Morales VA, Mulligan L, Faheem N, Windle HJ, Kelleher DP (2012) Alkyl hydroperoxide reductase: a candidate Helicobacter pylori vaccine Vaccine. 30(26), 3876-3884.

Corthésy-Theulaz Michetti P, Haas Davin C, Heitz Vaney A-C (1994) Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease Gastroenterology. 107(4), 1002-1011.

Satin B, Del G, Della V, Dusi S, Laudanna C, Tonello F (2000) The neutrophilactivating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor The Journal of experimental medicine. 191(9), 1467-1476.

Marchetti M, Arico B, Burroni D, Figura N, Rappuoli R, Ghiara P (1995) Development of a mouse model of Helicobacter pylori infection that mimics human disease Science. 267(5204), 1655-1658.

Marchetti M, Rossi M, Giannelli V, Giuliani MM, Pizza M, Censini S (1998) Protection against Helicobacter pylori infection in mice by intragastric vaccination with H pylori antigens is achieved using a non-toxic mutant of E coli heat-labile enterotoxin (LT) as adjuvant Vaccine. 16(1), 33-37.

C. Lee (2001) Vaccination Against Helicobacter pylori in Non‐Human Primate Models and Humans Scandinavian journal of immunology. 53(5), 437-442.

Rossi G, Ruggiero P, Peppoloni S, Pancotto L, Fortuna D, Lauretti L (2004) Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy Infection and immunity. 72(6), 3252-3259.

Stein M, Ruggiero P, Rappuoli R, Bagnoli F (2013) Helicobacter pylori CagA: from pathogenic mechanisms to its use as an anti-cancer vaccine.

Paolo Ruggiero, Stefano Censini (2014) Helicobacter pylori: A Brief History of a Still Lacking Vaccine Diseases. 2(2), 187-208. https://doi.org/10.3390/diseases2020187

Terradot L, Waksman G (2011) Architecture of the Helicobacter pylori Cag‐type IV secretion system FEBS Journal. 278(8), 1213-1222.

Fischer W (2011) Assembly and molecular mode of action of the Helicobacter pylori Cag type IV secretion apparatus FEBS Journal. 278(8), 1203-1212.

Cendron L, Zanotti G (2011) Structural and functional aspects of unique type IV secretory components in the Helicobacter pylori cag‐pathogenicity island FEBS Journal. 278(8), 1223-1231.

Stingl K, Müller S, Scheidgen-Kleyboldt G, Clausen M, Maier B (2010) Composite system mediates two-step DNA uptake into Helicobacter pylori Proceedings of the National Academy of Sciences. 107(3), 1184-1189.